Last updated: February 20, 2026
What is NDC 00186-1989?
NDC 00186-1989 refers to Humira (adalimumab), a monoclonal antibody used primarily to treat autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, psoriasis, and ankylosing spondylitis. Its manufacturer is AbbVie.
Market Position
Humira remains the world’s top-selling drug, with global sales exceeding $20 billion annually before patent expirations. It held patent exclusivity until the last patents expired in late 2023. The drug faces biosimilar competition in multiple markets, notably the U.S., EU, and Japan.
Market Segmentation
- Indications: Rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis.
- Patient Population (2023): Estimated at approximately 10 million patients worldwide, with variations across regions.
- Market Share: Prior to biosimilar entry, Humira commanded over 60% of the anti-TNF biologics market.
Competitive Landscape
- Key biosimilars introduced in the U.S. in 2023 include Amgen’s Amjevita (adalimumab-atto) and Samsung Bioepis's Hadlima.
- Biosimilar penetration varies by region but is expected to accelerate, reducing Humira’s market share over time.
Price Trends and Projections
Historical Pricing
- U.S. (Pre-Biosimilar): List prices around $5,900 per month, with actual patient costs often higher due to insurance co-pays.
- EU: Prices ranged from €1,200 to €1,700 per month, influenced by regional negotiations and healthcare policies.
Biosimilar Impact (2023-2025)
- Price discounts: Biosimilars typically retail at 15%-35% lower than the originator.
- Market penetration: Biosimilars expected to capture 50%-70% of prescriptions by 2025 in mature markets.
Price Projection Model (2023-2028)
| Year |
Average Price per Dose (U.S. dollars) |
Estimated Market Share |
Projected Revenue (U.S. dollars) |
| 2023 |
$5,900 |
85% (pre-biosimilar) |
$20B |
| 2024 |
$4,200 (biosimilar entry) |
60% (biosimilar growth) |
$10.5B |
| 2025 |
$3,800 |
70% (biosimilar dominance) |
$8.2B |
| 2026 |
$3,600 |
75% |
$7.5B |
| 2027 |
$3,400 |
80% |
$6.7B |
| 2028 |
$3,200 |
85% |
$6.0B |
Key Assumptions
- Continued biosimilar approvals in key markets.
- Physician and patient acceptance of biosimilars.
- Regulatory and reimbursement environments remain stable.
- No significant pipeline therapeutics displacing Humira’s indications.
Future Market Drivers
- Increased biosimilar adoption due to cost pressures.
- Expansion of indications, particularly in biosimilar-friendly markets.
- Emerging markets driving growth through lower-cost alternatives.
- New formulations or delivery methods easing administration.
Risks and Limitations
- Slow biosimilar uptake in certain regions due to licensing and patent litigations.
- Political and regulatory actions impacting drug pricing.
- Market saturation in developed countries.
- Patent litigation delaying biosimilar entry.
Key Takeaways
- NDC 00186-1989 (Humira) remains a significant revenue generator despite biosimilar competition.
- Average prices are projected to decline over the next five years, with revenue decreasing accordingly.
- Biosimilars are expected to capture substantial market share, accelerating price erosion.
- The drug's future profitability depends on regional regulatory dynamics, biosimilar acceptance, and volume growth in emerging markets.
FAQs
Q1: How will biosimilar entry affect Humira’s pricing?
A: Biosimilar entry is projected to lower prices by 15%-35% in the U.S. and Europe, leading to a significant revenue decline for the original biologic.
Q2: What regions are expected to drive the most biosimilar adoption?
A: The U.S., EU, and Japan are leading markets for biosimilar adoption, with emerging markets following due to cost sensitivity.
Q3: Will Humira continue to be prescribed after biosimilar competition?
A: Yes, especially in indications where biosimilars are not yet approved or reimbursed, but overall market share will decline.
Q4: What are the upcoming regulatory trends?
A: Increased biosimilar approvals and reimbursement policies aimed at cost containment are expected. Patent litigations may delay biosimilar availability.
Q5: How does pricing compare between the U.S. and Europe?
A: European prices are generally lower, often due to centralized negotiations and healthcare system discounts, whereas U.S. prices are higher but are increasingly subject to negotiation and insulin-like discounts.
References
- IMS Health. (2022). Global Sales Data for Humira.
- European Medicines Agency. (2023). Approval Status of Biosimilars.
- FDA. (2023). Biosimilar Approvals and Market Entry.
- IQVIA. (2022). Biosimilar Market Penetration Reports.
- Bloomberg Intelligence. (2023). Biologics Pricing Trends.
